Over the last two decades the outcomes of patients with amyloidosis have substantially improved with timely diagnosis, the use of chemotherapeutic agents and improved patient selection for autologous stem cell transplantation (ASCT); however, for patients who are diagnosed at later stages or who are ineligible for ASCT the prognosis is poorer. Recently, the introduction of daratumumab has shown promising results for patients with both newly diagnosed and relapsed/refractory amyloidosis and there have been a number of Phase II/III trials aiming to help guide treatment decision-making and improve patient outcomes.
In today’s podcast, Angela Dispenzieri, MD, of the Mayo Clinic, Rochester, MN, gives an overview of key updates in the treatment landscape of amyloidosis, as presented at the ninth annual meeting of the Society of Hematologic Oncology (SOHO 2021) congress.
The importance of addressing quality of life and improving symptom management in MPNs
Updates in the treatment and management of amyloidosis and the importance of the multidisciplinary team
Hemophilia: the current standard of care and the value of novel gene therapies
CLL highlights at EHA 2023: latest advances with the use of BTK inhibitors
Myeloma highlights at EHA 2023: CARTITUDE-4 & CARTITUDE-1 updates & the use of MRD in clinical practice
Lymphoma highlights at EHA 2023: sequencing bispecifics & CAR-T cells, bridging therapy & toxicity management
iwCAR-T Session IV: CAR-T therapy in CLL: challenges, combination approaches and ongoing trials
MDS 2023 highlights: managing anemia in lower-risk MDS & overcoming treatment failure in higher-risk disease
iwCAR-T Session III: CAR-T therapy in AML: ongoing challenges and strategies to improve patient outcomes
iwCAR-T Session II: CAR-T therapy in ALL: ongoing challenges and future outlooks
iwCAR-T Session I: CAR-T therapy in lymphoma and the role of bispecific antibodies
iwMyeloma Session III: reaching a cure for multiple myeloma and concepts that need to be addressed
The current role of stem cell transplantation in MPNs & how this may change with novel agents
iwMyeloma Session II: the tumor microenvironment and mechanisms of resistance to targeted therapies
iwMyeloma Session I: genomics of high-risk and smoldering multiple myeloma
The important role of transplantation in AML: improving outcomes for patients & the value of pre-transplant MRD
Insights into the changing role of chemotherapy in lymphoma
Comparing the ICC and WHO classifications for MDS and their impact on clinical practice
Managing and treating toxicities associated with CAR-T therapy: CRS, ICANS & infections
The growing role of immunotherapy in the treatment of ALL & moving away from stem cell transplantation
Create your
podcast in
minutes
It is Free
Good Mood Revolution
The Relaxback UK Show
On Call With Dr. Anselm Anyoha
Precision Medicine Forum Podcast
The Doctor’s Farmacy with Mark Hyman, M.D.
The Peter Attia Drive